The CTS newsletters are available in PDF and HTML formats. For optimal graphics performance use the freely available Adobe Acrobat Reader to view PDF documents.

Year Issue Topics Format
2024 1 New structure of the CTS coordination
2 Comparative global analysis of kidney transplant outcomes with regard to World Bank Group country classification by income level
(current, password-protected, CTS participants only)
2023 1 Impact of HDL and LDL cholesterol on kidney graft rejection and survival
2 Posttransplant blood pressure and kidney graft survival in pediatric patients
3 Recipient sex- and age-related differences in graft failure and mortality after kidney transplantation
4 Comparison of mortality and cause of death in kidney, liver and heart transplantation PDF | HTML
2022 1 Impact of SARS-CoV-2 infection on kidney transplant patient survival PDF | HTML
2 Predictors of graft failure in retransplants PDF | HTML
3 Impact and predictors of delayed graft function in kidney transplantation PDF | HTML
4 Joint analysis of pretransplant antibodies detected by CDC and SAB
2021 1 CTS Covid-19 Projects. Impact of cold ischemia time and HLA matching on ECD kidneys
2 Epitope versus traditional HLA matching
3 Impact of HLA match on kidneys from related living donors
4 Mortality of kidney transplant patients compared to normal population PDF | HTML
2020 1 Changes in the influence of donor age
2 Current impact of pre- and post-transplant DSA
3 Original disease and influence of donor age and cold ischemia time in liver transplantation
4 Influence of donor age in heart transplantation
2019 1 Pulse pressure and outcome in kidney transplantation
2 Late intra-patient tacrolimus trough level variability
3 Improvement of outcome in living donor kidney transplantation
4 Cold ischemia times, HLA matching and graft survival
2018 1 Time on dialysis and graft survival PDF | HTML
2 Maintenance immunosuppression with calcineurin inhibitors PDF | HTML
3 Influence on graft survival of acute rejection, DGF and HLA antibodies PDF | HTML
4 Incidence of post-transplant cancer in kidney graft recipients with pre-transplant malignancies PDF | HTML
2017 1 HLA match and graft survival, interactive PDF forms PDF | HTML
  2 Comparison living vs. deceased donor transplants PDF | HTML
  3 Pediatric liver transplantation PDF | HTML
  4 Influence of blood pressure and calcineurin inhibitors on kidney function PDF | HTML
2016 1 Recipient and donor age in pediatric patients PDF | HTML
  2 mTOR inhibitors and cancer PDF | HTML
  3 Antibody induction, DSA and sCD30 PDF | HTML
  4 Kidneys from elderly donors, crossmatch in liver transplantation PDF | HTML
2015 1 Steroid dosage and posttransplant cataract PDF | HTML
  2 Current impact of preformed antibodies PDF | HTML
  3 Impact of smoking, center-specific analysis PDF | HTML
  4 Changes in the recipient profile PDF | HTML
2014 1 Tacrolimus trough levels and kidney graft survival PDF | HTML
  2 Website access frequencies CTS newsletters PDF | HTML
  3 Age-adjusted improvement of kidney graft survival PDF | HTML
  4 CMV prophylaxis and cardiovascular death or death from infection PDF | HTML
2013 1 Kidney graft outcome, recipient-donor age combinations PDF | HTML
  2 HLA match and death due to infection in heart and liver transplantation PDF | HTML
  3 10-year analysis of prospective steroid withdrawal study PDF | HTML
  4 Steroid treatment and death due to infection in heart and lung transplant recipients PDF | HTML
2012 1 Long-term outcomes: serum creatinine, cataract, osteoporosis PDF | HTML
  2 Death with a functioning graft PDF | HTML
  3 HLA match and death due to infection, cardiovascular disease, cancer PDF | HTML
  4 Age and kidney graft survival and function PDF | HTML
2011 1 Recipient age, rejection and HLA matching PDF | HTML
  2 Cardiovascular death and death from infection PDF | HTML
  3 Respiratory tract cancer in kidney recipients PDF | HTML
  4 Statin treatment and death with a functioning kidney graft PDF | HTML
2010 1 Ischemia time and HLA matching PDF | HTML
  2 HLA matching and incidence of posttransplant lymphoma PDF | HTML
  3 Standardized tumor incidence rates PDF | HTML
  4 HLA and lung transplantation PDF | HTML
2009 1 Posttranspant hypercholesteremia and de-novo diabetes PDF | HTML
  2 Outcome comparison with different immunosuppressive regimens PDF | HTML
  3 Immunosuppressive regimens and pediatric kidney transplants PDF | HTML
  4 EBV and lymphoma PDF | HTML
2008 1 Time of rejection and long-term graft survival PDF | HTML
  2 Acute rejection and graft outcome in heart, lung, liver, pancreas transplantation PDF | HTML
  3 Preformed antibodies against HLA class I and II PDF | HTML
  4 Decrease or withdrawal of immunosuppression, HY gender effect PDF | HTML
2007 1 Completeness of follow up. HLA matching and short ischemia PDF | HTML
  2 Crossmatch analysis PDF | HTML
  3 Non-heartbeating donors, hypertensive donors, other marginal donors PDF | HTML
  4 Blood transfusions and antibodies against HLA and MICA PDF | HTML
2006 1 Influence of center size and early success rate on long-term outcome of kidney, heart and liver transplants PDF | HTML
  2 Antibody induction and incidence of non-Hodgkin lymphoma PDF | HTML
  3 Lymphoma and antibody induction non-renal transplants. Overall CTS statistics PDF | HTML
  4 ACEI/ARB treatment and long-term kidney graft survival PDF | HTML
2005 1 Donor age effect. Steroid withdrawal study PDF | HTML
  2 ABO incompatible kidney transplants PDF | HTML
  3 Preoperative cyclosporine PDF | HTML
  4 Successful control of posttransplant hypertension and kidney graft survival PDF | HTML
2004 1 Quality of HLA typing, HLA matching in kidney transplantation PDF | HTML
  2 Unrelated living donors, short ischemia, HLA matching PDF | HTML
  3 Hypertension and ACE inhibitors PDF | HTML
  4 Related donor and split liver transplants PDF | HTML
2003 1 TaXi expansion, incidence of rectal cancer PDF | HTML
  2 Influence of serum cholesterol in kidney and heart transplantation PDF | HTML
  3 Pretransplant sCD30 and HLA matching PDF | HTML
  4 Posttransplant cancer PDF | HTML
2002 1 Ischemic preservation time, anti-HLA antibodies PDF | HTML
  2 Analysis of sCD30 in kidney transplantation. Announcement of prospective sCD30 and anti-HLA antibody study PDF | HTML
  3 Combined kidney+liver and kidney+heart transplants PDF | HTML
2001 1 Software development. Generic cyclosporine PDF | HTML
  2 Cause of donor death PDF | HTML
3 New database TaXi. HLA matching and modern immunosuppression PDF | HTML
  4 Anti-HLA class I and class II antibodies PDF | HTML
2000 1 DNA typing project. Pretransplant risk categories PDF | HTML
  2 Improved transplant survival PDF | HTML
  3 Center-specific analysis PDF | HTML
  4 Update steroid withdrawal study, 4-year results PDF | HTML
1999 1 Prospective Steroid Withdrawal Study PDF | HTML
  2 Sibling Haplotype Project. Steroid Withdrawal Project PDF | HTML
  3 Role of IgA-anti-Fab Antibodies PDF | HTML
  4 CTS Website Update. Pretransplant Risk Assessment (Graft and patient survival) PDF | HTML
1998 1 Blood Pressure and Graft Survival PDF | HTML
  2 DNA Typing Project (A+B locus). Blood Pressure and Heart Transplants PDF | HTML
  3 CYA Dosage and Graft Outcome. Steroid-free Maintenance PDF | HTML
  4 Pretransplant CMV Status. CMV Prophylaxis PDF | HTML
1997 1 Posttransplant Malignancies PDF | HTML
  2 HLA-DR+DP Broad/Split Specificity Matches. Importance of DNA Typing PDF | HTML
  3 Randomized Transfusion Study PDF | HTML
  4 HIT Project PDF | HTML
1996 1 HLA Matching in Non-renal Transplantation HTML
  2 HLA matching in Heart Transplantation. Repeat Heart Transplants HTML
  3 Molecular Typing for HLA-DRB. Recipient Age in Renal Transplantation PDF | HTML
  4 Cold Ischemic Preservation Times. HLA Matching and Graft Survival with Short Cold Ischemia PDF | HTML
  5 Early Immunological Rejection and Chronic Graft Loss. Taboo Mismatches PDF | HTML
1995 1 "Permissible" HLA mismatches HTML
  2 HIT Trial for highly immunized patients HTML
  3 "Graft Adaption" HTML
  4 Induction Treatment with OKT3 HTML
1994 1 Patient Survival after Diagnosis of Posttransplant Lymphomas HTML
  2 HLA Matching in Heart Transplantation. Influence of Donor Age HTML
  3 Maintenance Immunosuppression in Renal Transplant Recipients HTML
  4 Steroid Withdrawal Project HTML
1993 1 HLA Compatibility in Liver Transplantation HTML
  2 Kidney Preservation Methods HTML
  3 Impact of AB0 Compatibility/Incompatibility on Graft Survival HTML
  4 XCOMB Allocation Method HTML
  5 Posttransplant non-Hodgkin's Lymphomas HTML
1992 1 Donor Age in Liver and Pancreas Transplantation. Relevance of HLA-A and -B Antigen Splits HTML
  2 10th CTS Anniversary Symposium HTML
  3 Discrepancies between Serological and DNA Typing HTML
  4 Graft and Patient Survival for "Good", "Mediocre" or "Poor" Risk Patients HTML
1991 1 Kidney Transplants from Live Unrelated Donors HTML
  2 Analysis of Pancreas Transplants HTML
  3 CMV Status of Transplant Recipients and Donors HTML
  4 DNA-RFLP Project HTML
  5 Donor Age in Kidney and Heart Transplantation HTML
1990 1 Evolution of Kidney and Heart Transplant Studies HTML
  2 Transplant Results for Different Diseases HTML
  3 Sequential Immunosuppression for Kidney and Heart Transplantation HTML
  4 Sequential Immunosuppression with OKT3 rather than ATG/ALG Induction HTML
  5 Yearly Success Rates for Kidney, Heart, Liver and Pancreas Transplants HTML
  6 Estimation of Long-Term Kidney Graft Survival Rates HTML
1989 1 HLA Matching in Second Transplants HTML
  2 Sequential Immunosuppression HTML
  3 Role of Remote Positive Crossmatch HTML
  4 Survival of father to child as compared to mother to child transplants HTML
  5 Heart and kidney transplants and the alleged nephrotoxic effect of Cyclosporine HTML
  6 Pancreas transplants HTML
  7 Matching for HLA split antigens HTML
1988 1 Influence of recipient/donor age HTML
  2 59 verified AB0 incompatible cadaver transplants HTML
  3 Pretransplant transfusions HTML
  4 Importance of HLA antigen "splits" HTML
  5 Preliminary analysis of immunosuppression questionnaires HTML
  6 Influence of HLA matching with or without Cyclosporine HTML
1987 1 HLA-B+DR mismatches in first cadaver transplants HTML
  2 Influence of recipient age HTML
  3 Age and patient survival in different disease categories HTML
  4 Explanation of clinical grades HTML
  5 Type and time of dialysis HTML
  6 Type and time of dialysis. Influence of HLA-B+DR mismatches HTML
  7 First and second transplants with Cyclosporine. Importance of good quality HLA typing HTML
1986 1 Comparison cadaver transplants with or without Cyclosporine HTML
  2 Recipient/Donor age, with or without Cyclosporine HTML
  3 Preformed lymphocytotoxic antibodies HTML
  4 High level antibodies and HLA matching HTML
  5 Retransplants HTML
  6 Pretransplant transfusions HTML
  7 Influence of HLA-B+DR matching on Cyclosporine-treated transplants HTML
  8 Patient and graft survival: Cyclosporine, original disease, risk factors HTML
1985 1 Effect of HLA-A, -B and -DR Mismatches on graft survival HTML
  2 Effect of Cyclosporine on graft survival HTML
  3 Effect of Cyclosporine and HLA-B, -DR mismatches on graft survival HTML
  4 Survival rates for "good", "moderate" or "poor" Risk patients in Europe, North America and other continents HTML
  5 Comparison of Cyclosporine versus conventional immunosuppression in children HTML
  6 Introduction of CTS sera sets. Results of crossmatch analysis HTML
1984 1 Cross match analysis correlation of HLA matching with graft outcome HTML
  2 Analysis of extended red cell antigen data, the complement of Bf markers and whether or not donor was transfused HTML
  3 Survival in patients with or without CyA HTML
  4 Influence of ischemia times on graft survival HTML
  5 Differential effect of HLA matching with ischemia times HTML
1983 1 Transplant results in relation to preformed lymphocytotoxic antibodies HTML
  2 Analysis of different immunosuppressive protocols. DR6 effect on graft survival HTML
  3 Combined analysis of HLA-B plus HLA-DR on graft survival HTML
  4 Matching for HLA-A, -B and -DR HTML


This website uses cookies to deliver our services. By continuing to visit this site you agree to our use of cookies.
More information are found in our data protection statement.